 PolarityTE NASDAQ: PTE shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints. In the companys multi-center randomized controlled trial, 70 of patients treated with SkinTE plus standard of care showed wound closure at 12 weeks, compared with 34 of patients receiving standard of care alone. 